NASDAQ:SILO Silo Pharma (SILO) Stock Price, News & Analysis $0.42 0.00 (-0.24%) Closing price 05/7/2026 04:00 PM EasternExtended Trading$0.41 -0.01 (-2.14%) As of 05/7/2026 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Silo Pharma Stock (NASDAQ:SILO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Silo Pharma alerts:Sign Up Key Stats Today's Range$0.42▼$0.4450-Day Range$0.32▼$0.6752-Week Range$0.22▼$1.13Volume196,365 shsAverage Volume3.07 million shsMarket Capitalization$6.83 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Silo Pharma, Inc. (NASDAQ:SILO) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel psychedelic and related synthetic therapies. Headquartered in New York City, the company applies proprietary chemistry and targeted drug delivery approaches to advance candidates that address critical unmet needs across oncology, neurology and mental health. The company’s preclinical and early-stage clinical pipeline comprises several programs that explore serotonin receptor modulators, synthetic analogs of classic psychoactive compounds and neuroprotective agents. Key initiatives include research into treatments for chemotherapy-induced neurotoxicity, glioblastoma, neurodegenerative disorders and mood conditions such as depression and post-traumatic stress disorder. Silo Pharma leverages strategic collaborations and material licensing agreements with leading academic institutions to accelerate its research efforts. Originally founded as Elicio Therapeutics in 2019, the firm rebranded to Silo Pharma in 2021 to underscore its specialized focus on psychedelics and novel CNS therapies. In addition to its U.S. operations, the company engages in collaborative research activities with partners in Canada and Europe. Silo Pharma’s leadership team brings together expertise in pharmaceutical R&D, regulatory strategy and business development to position the company for growth in the emerging psychedelics sector.AI Generated. May Contain Errors. Read More Silo Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks8th Percentile Overall ScoreSILO MarketRank™: Silo Pharma scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingSilo Pharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageSilo Pharma has only been the subject of 1 research reports in the past 90 days.Read more about Silo Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Silo Pharma is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Silo Pharma is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSilo Pharma has a P/B Ratio of 0.89. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Silo Pharma's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.29% of the float of Silo Pharma has been sold short.Short Interest Ratio / Days to CoverSilo Pharma has a short interest ratio ("days to cover") of 0.03, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Silo Pharma has recently increased by 58.61%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSilo Pharma does not currently pay a dividend.Dividend GrowthSilo Pharma does not have a long track record of dividend growth. News and Social Media1.3 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Silo Pharma this week, compared to 2 articles on an average week.Search Interest6 people have searched for SILO on MarketBeat in the last 30 days. MarketBeat Follows7 people have added Silo Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Silo Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders2.22% of the stock of Silo Pharma is held by insiders.Percentage Held by Institutions5.58% of the stock of Silo Pharma is held by institutions.Read more about Silo Pharma's insider trading history. Receive SILO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Silo Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SILO Stock News HeadlinesSilo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain InjuryMay 7 at 8:05 AM | globenewswire.comSilo Pharma (SILO) Expected to Announce Quarterly Earnings on FridayMay 1, 2026 | americanbankingnews.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account. | Profits Run (Ad)Silo Pharma, Inc.: Silo Pharma's PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSDApril 30, 2026 | finanznachrichten.deSilo Pharma’s PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSDApril 30, 2026 | markets.businessinsider.comSilo Pharma's PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSDApril 29, 2026 | globenewswire.comSilo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, QwikagentsApril 22, 2026 | globenewswire.comSilo Pharma, Inc.: Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon ...April 20, 2026 | finanznachrichten.deSee More Headlines SILO Stock Analysis - Frequently Asked Questions How have SILO shares performed this year? Silo Pharma's stock was trading at $0.34 at the start of the year. Since then, SILO stock has increased by 23.5% and is now trading at $0.42. How were Silo Pharma's earnings last quarter? Silo Pharma, Inc. (NASDAQ:SILO) released its quarterly earnings data on Friday, March, 27th. The company reported $0.03 earnings per share (EPS) for the quarter. The company earned $0.02 million during the quarter. Silo Pharma had a negative trailing twelve-month return on equity of 83.53% and a negative net margin of 5,870.83%. Who are Silo Pharma's major shareholders? Top institutional shareholders of Silo Pharma include AdvisorShares Investments LLC (4.08%). Insiders that own company stock include Eric Weisblum and Daniel E Ryweck. View institutional ownership trends. How do I buy shares of Silo Pharma? Shares of SILO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Silo Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Silo Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Citius Pharmaceuticals (CTXR), Sunshine Biopharma (SBFM), AbbVie (ABBV) and Biorestorative Therapies (BRTX). Company Calendar Last Earnings3/27/2026Today5/08/2026Next Earnings (Estimated)5/08/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 SILO's financial health is in the Green zone, according to TradeSmith. SILO has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryApparel Current SymbolNASDAQ:SILO CIK1514183 Websilopharma.com Phone(718) 400-9031FaxN/AEmployees2Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$4.23 million Net Margins-5,870.83% Pretax Margin-5,863.92% Return on Equity-83.53% Return on Assets-63.70% Debt Debt-to-Equity RatioN/A Current Ratio11.37 Quick Ratio11.37 Sales & Book Value Annual Sales$70 thousand Price / Sales97.62 Cash FlowN/A Price / Cash FlowN/A Book Value$0.47 per share Price / Book0.89Miscellaneous Outstanding Shares16,270,000Free Float15,906,000Market Cap$6.83 million OptionableNot Optionable Beta0.65 10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:SILO) was last updated on 5/8/2026 by MarketBeat.com Staff. From Our PartnersMassive Data Leak Exposes 512,000-Line Code That Could Change Society Forever"You won't believe what I discovered at 4 World Trade Center" When our financial media correspondent travel...Chaikin Analytics | SponsoredWhy I flew on a tiny helicopter next to a potential nuclear bomb targetSatellite Confirms: Elon Musk Activating Strange 'Dark Energy' Across U.S. South Confirmed by satellites 30...Altimetry | SponsoredElon’s AI supercomputer just went live. Here’s my #1 stock.Is Elon about to trigger another 315X opportunity? Elon gave Tesla investors the chance to make more than 3...InvestorPlace | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIs the SpaceX IPO “Rigged?”The SpaceX IPO filing is official, with 21 banks - including JPMorgan, Goldman Sachs, and Morgan Stanley - pre...The Oxford Club | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silo Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Silo Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
